Evaluation of the effect of glucosamine administration on biomarkers of cartilage and bone metabolism in bicycle racers

Momomura,Rei; Naito,Kiyohito; Igarashi,Mamoru; Watari,Taiji; Terakado,Atsuhiko; Oike,Shinji; Sakamoto,Koji; Nagaoka,Isao; Kaneko,Kazuo

doi:10.3892/mmr.2013.1289

Evaluation of the effect of glucosamine administration on biomarkers of cartilage and bone metabolism in bicycle racers

Authors:
- Rei Momomura
- Kiyohito Naito
- Mamoru Igarashi
- Taiji Watari
- Atsuhiko Terakado
- Shinji Oike
- Koji Sakamoto
- Isao Nagaoka
- Kazuo Kaneko
View Affiliations

Affiliations: Department of Medicine for Motor Organs, Juntendo University Graduate School of Medicine, Tokyo 113‑8421, Japan, Department of Host Defense and Biochemical Research, Juntendo University Graduate School of Medicine, Tokyo 113‑8421, Japan, Department of Rehabilitation Medicine, Juntendo University Graduate School of Medicine, Tokyo 113‑8421, Japan, Japan Keirin School, Shizuoka 410‑2402, Japan, Koyo Chemical Co., Ltd., Tokyo 102‑0072, Japan
Published online on: January 25, 2013 https://doi.org/10.3892/mmr.2013.1289
Pages: 742-746

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, the effect of glucosamine administration (1.5 or 3 g/day) on cartilage and bone metabolism was investigated in bicycle racers, using cartilage‑ and bone‑specific biomarkers, including C‑terminal cross‑linked telopeptides of type II collagen (CTX‑II), C‑terminal propeptides of type II procollagen (CPII), N‑terminal telopeptides of bone‑specific type I collagen (NTx) and bone alkaline phosphatase (BAP). The results indicate that CPII (a marker of type II collagen synthesis) was not substantially changed, however, CTX‑II (a marker of type II degradation) was reduced by glucosamine administration, particularly at a dose of 3 g/day. Consistent with these observations, the ratio of CTX‑II/CPII was reduced by glucosamine administration and the effect of glucosamine was dose‑dependent. By contrast, the levels of NTx (a bone resorption marker) and BAP (a bone formation marker) were not altered by glucosamine administration. A previous study by this group reported that glucosamine exerts a chondroprotective action in soccer players by preventing type II collagen degradation but maintaining type II collagen synthesis. Together these observations indicate that glucosamine may exert a chondroprotective action by preventing type II collagen degradation in athletes of various sports, including soccer players and bicycle racers.

View Figures

View References

1	O’Kane JW, Hutchinson E, Atley LM and Eyre DR: Sport-related differences in biomarkers of bone resorption and cartilage degradation in endurance athletes. Osteoarthritis Cartilage. 14:71–76. 2006.PubMed/NCBI
2	Roos H, Dahlberg L, Hoerrner LA, Lark MW, Thonar EJ, Shinmei M, Lindqvist U and Lohmander LS: Markers of cartilage matrix metabolism in human joint fluid and serum: the effect of exercise. Osteoarthritis Cartilage. 3:7–14. 1995. View Article : Google Scholar : PubMed/NCBI
3	Qi C and Changlin H: Effects of moving training on histology and biomarkers levels of articular cartilage. J Surg Res. 135:352–363. 2006. View Article : Google Scholar : PubMed/NCBI
4	Qi C, Changlin H and Zefeng H: Matrix metalloproteinases and inhibitor in knee synovial fluid as cartilage biomarkers in rabbits: the effect of high-intensity jumping exercise. J Surg Res. 140:149–157. 2007. View Article : Google Scholar : PubMed/NCBI
5	Kim HJ, Lee YH and Kim CK: Biomarkers of muscle and cartilage damage and inflammation during a 200 km run. Eur J Appl Physiol. 99:443–447. 2007. View Article : Google Scholar : PubMed/NCBI
6	Buckwalter JA and Lane NE: Does participation in sports cause osteoarthritis? Iowa Orthop J. 17:80–89. 1997.PubMed/NCBI
7	Buckwalter JA and Lane NE: Athletics and osteoarthritis. Am J Sports Med. 25:873–881. 1997. View Article : Google Scholar : PubMed/NCBI
8	Creighton DL, Morgan AL, Boardley D and Brolinson PG: Weight-bearing exercise and markers of bone turnover in female athletes. J Appl Physiol. 90:565–570. 2001.PubMed/NCBI
9	Garnero P, Rousseau JC and Delmas PD: Molecular basis and clinical use of biochemical markers of bone, cartilage and synovium in joint diseases. Arthritis Rheum. 43:953–968. 2000. View Article : Google Scholar : PubMed/NCBI
10	Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD and Vignon E: Cross sectional evaluation of biochemical markers of bone, cartilage and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis. 60:619–626. 2001. View Article : Google Scholar
11	Poole AR: Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis. Rheum Dis Clin North Am. 29:803–818. 2003. View Article : Google Scholar : PubMed/NCBI
12	Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, Rosenquist C and Qvist P: Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone. 29:209–215. 2001. View Article : Google Scholar : PubMed/NCBI
13	Poole AR, Ionescu M, Fitzcharles MA and Billinghurst RC: The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods. 294:145–153. 2004. View Article : Google Scholar : PubMed/NCBI
14	Shinmei M, Ito K, Matsuyama S, Yoshihara Y and Matsuzawa K: Joint fluid carboxy-terminal type II procollagen peptide as a marker of cartilage collagen biosynthesis. Osteoarthritis Cartilage. 1:121–128. 1993. View Article : Google Scholar : PubMed/NCBI
15	Garnero P and Delmas PD: Biomarkers in osteoarthritis. Curr Opin Rheumatol. 15:641–646. 2003. View Article : Google Scholar
16	Rousseau JC and Delmas PD: Biological markers in osteoarthritis. Nat Clin Pract Rheumatol. 3:346–356. 2007. View Article : Google Scholar
17	Warner SE, Shaw JM and Dalsky GP: Bone mineral density of competitive male mountain and road cyclists. Bone. 30:281–286. 2002. View Article : Google Scholar : PubMed/NCBI
18	Smathers AM, Bemben MG and Bemben DA: Bone density comparisons in male competitive road cyclists and untrained controls. Med Sci Sports Exerc. 41:290–296. 2009. View Article : Google Scholar : PubMed/NCBI
19	Stewart AD and Hannan J: Total and regional bone density in male runners, cyclists and controls. Med Sci Sports Exerc. 32:1373–1377. 2000. View Article : Google Scholar : PubMed/NCBI
20	Nichols JF, Palmer JE and Levy SS: Low bone mineral density in highly trained male master cyclists. Osteoporos Int. 14:644–649. 2003. View Article : Google Scholar : PubMed/NCBI
21	Rector RS, Rogers R, Ruebel M and Hinton PS: Participation in road cycling vs running is associated with lower bone mineral density in men. Metabolism. 57:226–232. 2008. View Article : Google Scholar : PubMed/NCBI
22	Huang SH, Johnson K and Pipe AL: The use of dietary supplements and medications by Canadian athletes at the Atlanta and Sydney Olympic Games. Clin J Sport Med. 16:27–33. 2006. View Article : Google Scholar : PubMed/NCBI
23	Froiland K, Koszewski W, Hingst J and Kopecky L: Nutritional supplement use among college athletes and their sources of information. Int J Sport Nutr Exerc Metab. 14:104–120. 2004.PubMed/NCBI
24	Schwenk TL and Costley CD: When food becomes a drug: nonanabolic nutritional supplement use in athletes. Am J Sports Med. 30:907–916. 2002.PubMed/NCBI
25	Dascombea BJ, Karunaratna M, Cartoon J, Fergie B and Goodmana C: Nutritional supplementation habits and perceptions of elite athletes within a state-based sporting institute. J Sci Med Sport. 13:274–280. 2010. View Article : Google Scholar : PubMed/NCBI
26	Gorsline RT and Kaeding CC: The use of NSAIDs and nutritional supplements in athletes with osteoarthritis: prevalence, benefits and consequences. Clin Sports Med. 24:71–82. 2005. View Article : Google Scholar : PubMed/NCBI
27	Ostojic SM, Arsic M, Prodanovic S, Vukovic J and Zlatanovic M: Glucosamine administration in athletes: effects on recovery of acute knee injury. Res Sports Med. 15:113–124. 2007. View Article : Google Scholar : PubMed/NCBI
28	McAlindon TE, Lavalley MP, Gulin JP and Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 283:1469–1475. 2000. View Article : Google Scholar : PubMed/NCBI
29	Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE and Gossett C: Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet. 357:251–256. 2001. View Article : Google Scholar
30	Pavelká K, Gatterová J, Olejarová M, Machacek S, Giacovelli G and Rovati LC: Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 162:2113–2123. 2002.PubMed/NCBI
31	Igarashi M, Kaga I, Takamori Y, Sakamoto K, Miyazawa K and Nagaoka I: Effects of glucosamine derivatives and uronic acids on the production of glycosaminoglycans by human synovial cells and chondrocytes. Int J Mol Med. 27:821–827. 2011.PubMed/NCBI
32	Nakamura H, Shibakawa A, Tanaka M, Kato T and Nishioka K: Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol. 22:293–299. 2004.PubMed/NCBI
33	Derfoul A, Miyoshi AD, Freeman DE and Tuan RS: Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation. Osteoarthr Cartil. 15:646–655. 2007. View Article : Google Scholar : PubMed/NCBI
34	Yoshimura M, Sakamoto K, Tsuruta A, Yamamoto T, Ishida K, Yamaguchi H and Nagaoka I: Evaluation of the effect of glucosamine administration on biomarkers for cartilage and bone metabolism in soccer players. Int J Mol Med. 24:487–494. 2009.PubMed/NCBI
35	Cahue S, Sharma L, Dunlop D, Ionescu M, Song J, Lobanok T, King L and Poole AR: The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. Osteoarthritis Cartilage. 15:819–823. 2007. View Article : Google Scholar : PubMed/NCBI
36	Sharif M, Kirwan J, Charni N, Sandell LJ, Whittles C and Garnero P: A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis - association with disease progression. Rheumatol. 46:938–943. 2007. View Article : Google Scholar : PubMed/NCBI
37	Igarashi M, Sakamoto K and Nagaoka I: Effect of glucosamine, a therapeutic agent for osteoarthritis, on osteoblastic cell differentiation. Int J Mol Med. 28:373–379. 2011.PubMed/NCBI
38	Wang SX, Laverty S, Dumitriu M, Plaas A and Grynpas MD: The effects of glucosamine hydrochloride on subchondral bone changes in any animal model of osteoarthritis. Arthritis Rheum. 56:1537–1548. 2007. View Article : Google Scholar : PubMed/NCBI